Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
Clarus Therapeutics Holdings Inc
Accounts Receivables
Clarus Therapeutics Holdings Inc
Accounts Receivables Peer Comparison
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/jnj.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/bmy.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/pfe.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/mrk.png)
![](https://ik.imagekit.io/kkbzr2uz4cp/stock/nyse/lly.png)
Competitive Accounts Receivables Analysis
Latest Figures & CAGR of Competitors
Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Clarus Therapeutics Holdings Inc
NASDAQ:CRXT
|
Accounts Receivables
$6.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
![]() |
Johnson & Johnson
NYSE:JNJ
|
Accounts Receivables
$14.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
![]() |
Bristol-Myers Squibb Co
NYSE:BMY
|
Accounts Receivables
$9.2B
|
CAGR 3-Years
9%
|
CAGR 5-Years
15%
|
CAGR 10-Years
18%
|
![]() |
Pfizer Inc
NYSE:PFE
|
Accounts Receivables
$11B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
2%
|
![]() |
Merck & Co Inc
NYSE:MRK
|
Accounts Receivables
$11.4B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
5%
|
![]() |
Eli Lilly and Co
NYSE:LLY
|
Accounts Receivables
$7.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
See Also
What is Clarus Therapeutics Holdings Inc's Accounts Receivables?
Accounts Receivables
6.3m
USD
Based on the financial report for Dec 31, 2021, Clarus Therapeutics Holdings Inc's Accounts Receivables amounts to 6.3m USD.
What is Clarus Therapeutics Holdings Inc's Accounts Receivables growth rate?
Accounts Receivables CAGR 1Y
44%
Over the last year, the Accounts Receivables growth was 44%.